EP2900293A1 - Système de traitement de plaies - Google Patents

Système de traitement de plaies

Info

Publication number
EP2900293A1
EP2900293A1 EP13722291.5A EP13722291A EP2900293A1 EP 2900293 A1 EP2900293 A1 EP 2900293A1 EP 13722291 A EP13722291 A EP 13722291A EP 2900293 A1 EP2900293 A1 EP 2900293A1
Authority
EP
European Patent Office
Prior art keywords
negative pressure
wound
therapy
therapeutic treatment
wound dressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13722291.5A
Other languages
German (de)
English (en)
Inventor
Hans Smola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paul Hartmann AG
Original Assignee
Paul Hartmann AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paul Hartmann AG filed Critical Paul Hartmann AG
Priority to EP13722291.5A priority Critical patent/EP2900293A1/fr
Publication of EP2900293A1 publication Critical patent/EP2900293A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/05—Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/88—Draining devices having means for processing the drained fluid, e.g. an absorber
    • A61M1/882—Draining devices provided with means for releasing antimicrobial or gelation agents in the drained fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/91—Suction aspects of the dressing
    • A61M1/915—Constructional details of the pressure distribution manifold
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D1/00—Surgical instruments for veterinary use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/00217—Wound bandages not adhering to the wound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00727—Plasters means for wound humidity control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00727—Plasters means for wound humidity control
    • A61F2013/00748—Plasters means for wound humidity control with hydrocolloids or superabsorbers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00727—Plasters means for wound humidity control
    • A61F2013/00748—Plasters means for wound humidity control with hydrocolloids or superabsorbers
    • A61F2013/00753—Plasters means for wound humidity control with hydrocolloids or superabsorbers superabsorbent fabric of cloth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/91—Suction aspects of the dressing
    • A61M1/916—Suction aspects of the dressing specially adapted for deep wounds

Definitions

  • the invention relates generally to wound therapy, and more particularly to devices or systems for wound therapy.
  • Negative wound therapy also known as topical negative pressure (TNP), negative pressure wound therapy (NPWT) or vacuum assisted closure (VAC), has long been recognized, but has been particularly prevalent since the mid-term / Late 1990s increasingly used.
  • TNP topical negative pressure
  • NPWT negative pressure wound therapy
  • VAC vacuum assisted closure
  • a wound filling material is usually inserted into the wound, the wound area is covered with a foil and a negative pressure is generated in the wound space by means of a drainage tube and a vacuum pump.
  • the negative pressure causes effective wound cleansing by removing wound exudate.
  • Further advantages include promotion of granulation tissue formation and reduction of wound edema formation.
  • vacuum assisted closure treatment already suggests, negative pressure therapy is usually performed until the wound is closed. Wound closure is generally considered to be achieved when there is a layer of epidermis over the former wound site. Wound closure can be achieved through healing processes or through surgical procedures.
  • Low pressure therapy is particularly useful in acute or chronic wounds such as ulcers (e.g., pressure ulcers, diabetic, neuropathic or venous ulcers), traumatic wounds, refractory wounds, infected wounds, postoperative wounds, probed fistulas, and skin flaps and skin grafts.
  • Chronic wounds are characterized by slow or absent wound healing.
  • WO 1993/009727 A1 describes a device for promoting wound healing by the application of negative pressure on the area of the skin having the wound and surrounding the wound.
  • the device according to WO 1993/009727 AI comprises a vacuum device for generating the negative pressure, an airtight covering of the wound, which is in a functional connection with the vacuum device, and a wound dressing for positioning on the wound inside the airtight cover.
  • the wound dressing is preferably an open-cell polymer foam, for example polyester foam.
  • open cell polymer foam for example polyester foam.
  • Wound wound therapy devices are also commercially available, ranging from small, portable devices that allow patients some mobility, to stationary devices, such as in long-term care facilities.
  • the object of the present invention is to provide a wound therapy which positively influences the physiological condition of the wound. Furthermore, a wound therapy should be provided, which affects the patient as little as possible. In addition, it was an object to improve the cost of wound therapy, but without compromising the clinical efficiency of wound therapy, or even increasing clinical efficiency, or providing systems that allow for such improved wound therapy.
  • the impairment of the patient compared to the conventional negative pressure therapy could be improved, especially with regard to the pain sensation and the mobility of the patient.
  • the invention according to a first aspect comprises a negative pressure therapy device for use in a wound therapy, which comprises a first therapy section, in which negative pressure therapy is performed by means of the negative pressure therapy device, and a subsequent second therapy section, in which uses the wound therapy a wound dressing is carried out without generating a negative pressure, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer.
  • the invention relates to a product for use in the therapeutic treatment of wounds on the human or animal body, the product comprising a negative pressure therapy device, characterized in that the therapeutic treatment comprises a first therapy section in which the negative pressure therapy by means of the negative pressure therapy device is performed, and a subsequent second therapy section, in which the therapeutic treatment is performed using a wound dressing without generating a negative pressure, wherein the wound dressing comprises an absorbent body which comprises a swellable polymer, in particular a superabsorbent polymer.
  • the product or the negative pressure therapy device is therefore claimed explicitly in connection with its specific medical application or indication, namely the therapeutic treatment of wounds, which is based on the special new therapeutic application or the special new treatment plan, which / two successive Therapy sections includes.
  • the product may consist solely of the negative pressure therapy device.
  • wound therapy and therapeutic treatment of wounds are hereby used interchangeably. It can wounds on the human or animal body are treated, preferably the treatment takes place on the human body.
  • a negative pressure therapy device is a device for negative pressure therapy of wounds.
  • the present invention further includes the use of a negative pressure therapy device in the therapeutic treatment of wounds on the human or animal body, characterized in that the therapeutic treatment comprises a first therapy section, in which the negative pressure therapy is performed by means of the device, and that the therapeutic treatment a subsequent second treatment section, which is performed using a wound dressing without generating a negative pressure, wherein in the second therapy section, a wound dressing is used, which contains a absorbent body comprising a swellable polymer, in particular a superabsorbent polymer.
  • the invention provides a wound dressing for use in a wound therapy, comprising a first therapy section, in which wound therapy is performed under negative pressure, and a subsequent second therapy section, in which wound therapy using the wound dressing without producing a wound therapy Underpressure, preferably in moist or moist wet environment, is performed.
  • the wound dressing is preferably intended specifically for use in wound therapy in a moist or wet-moist environment.
  • the invention relates to a wound dressing for use in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent body comprising a swellable polymer, in particular a superabsorbent polymer, characterized in that the therapeutic treatment comprises a first therapy section in which a wound therapy is performed by means of negative pressure, and a subsequent second treatment section, in which the therapeutic treatment is performed using the wound dressing without generating a negative pressure.
  • the wound dressing herein is expressly claimed in the context of its specific medical application or indication, namely, the therapeutic treatment of wounds based on the particular new therapeutic mode of administration or the particular new therapy regimen, which are two consecutive includes the following therapy sections.
  • the second aspect of the invention relates to a product for use in the therapeutic treatment of wounds on the human or animal body, the product comprising a wound dressing, and wherein the wound dressing comprises an absorbent body comprising a swellable polymer, in particular a superabsorbent Polymer, characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of a device for negative pressure therapy of wounds, and a subsequent second therapy section, in which the therapeutic treatment using the wound dressing without generating a negative pressure is carried out.
  • the product may consist solely of the wound dressing.
  • the present invention further encompasses the use of a wound dressing in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent body comprising a swellable polymer, in particular a superabsorbent polymer characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of a device for negative pressure therapy of wounds, and in that the therapeutic treatment comprises a subsequent second treatment section, which is performed using the wound dressing without generating a negative pressure.
  • the wound dressing comprises an absorbent body comprising a swellable polymer, in particular a superabsorbent polymer characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of a device for negative pressure therapy of wounds, and in that the therapeutic treatment comprises a subsequent second treatment section, which is performed using the wound dressing without generating a negative pressure.
  • the invention provides a combination of apparatus for performing wound therapy by means of negative pressure and wound dressing for application in a wound therapy comprising a first therapy section, in which wound therapy is performed using the device under negative pressure, and a subsequent one Second therapy section comprises, in which wound therapy using the wound dressing without generating a negative pressure, preferably in a moist or wet-wet environment, is performed, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer.
  • the third aspect of the invention relates to a product for use in the therapeutic treatment of wounds on the human or animal body, the product comprising a device for negative pressure therapy of wounds and a wound dressing, and wherein the wound dressing comprises an absorbent body which a swellable polymer, in particular a superabsorbent polymer, characterized in that the therapeutic treatment comprises a first treatment section, in which negative pressure therapy is performed by means of a device for negative pressure therapy of wounds, and a subsequent second therapy section, in which the therapeutic treatment Use of the wound dressing is carried out without generating a negative pressure.
  • the combination or the product is expressly claimed in connection with their specific medical application or indication, namely the therapeutic treatment of wounds, which comprises two successive therapy sections.
  • the present invention further comprises the use of a combination of a device for negative pressure therapy of wounds and a wound dressing in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer, characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of the device for negative pressure therapy of wounds, and one thereon following second therapy section, in which the therapeutic treatment is performed using the wound dressing without generating a negative pressure.
  • a further subject of the invention is a method for the therapeutic treatment of wounds on the human or animal body, comprising i) a first therapy section, in which negative pressure therapy is carried out by means of a device for negative pressure therapy of wounds,
  • a subsequent second treatment section in which the therapeutic treatment (preferably in a moist or wet-moist environment) is carried out using a second wound dressing without generating a negative pressure
  • the second wound dressing comprises an absorbent body comprising a swellable polymer, in particular a superabsorbent polymer.
  • the first wound dressing is preferably a wound dressing which comprises an open-cell foam, for example an open-celled polyurethane foam.
  • an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer.
  • the invention also relates, in particular, to a method for the therapeutic treatment of wounds on the human or animal body i) a first therapy section, in which negative pressure therapy is carried out by means of a device for negative pressure therapy of wounds for combating inflammation and / or edema mobilization in the wound area, wherein the device for performing wound therapy by means of negative pressure
  • the second wound dressing comprises an absorbent body comprising a swellable polymer, in particular a superabsorbent polymer.
  • the subject matter of the invention is a combination of a device for negative pressure therapy of wounds and a wound dressing (the combination being provided) for use in the therapeutic treatment of wounds on the human or animal body, the wound dressing comprising an absorbent body comprising a swellable polymer, in particular a superabsorbent polymer, characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of the device, and a subsequent second therapy section, in which the therapeutic treatment is performed using the wound dressing without creating a negative pressure becomes.
  • the invention according to the first aspect therefore provides:
  • An open-cell foam for use in the therapeutic treatment of wounds on the human or animal body characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of a negative pressure therapy device comprising the open-cell foam, and comprises a subsequent second therapy section, in which the therapeutic treatment is carried out using a wound dressing without generating a negative pressure, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer.
  • the invention according to the first aspect provides
  • a swellable polymer for use in the therapeutic treatment of wounds on the human or animal body characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of a negative pressure therapy device comprising the swellable polymer, and comprises a subsequent second therapy section, in which the therapeutic treatment is carried out using a wound dressing without generating a negative pressure, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer.
  • the invention relates in this first aspect:
  • an open-cell foam for the preparation of a vacuum device for use in the therapeutic treatment of wounds on the human or animal body, characterized in that the therapeutic treatment comprises a first therapy section, in which the negative pressure therapy is performed by means of the open-cell foam negative pressure therapy device, and a subsequent second therapy section, in which the therapeutic treatment is carried out using a wound dressing without generating a negative pressure, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer.
  • the open-cell foam is used in particular for producing a wound dressing of the vacuum device.
  • the invention according to the alternative embodiment relates to: The use of a swellable polymer for the production of a vacuum device for use in the therapeutic treatment of wounds on the human or animal body, characterized in that the therapeutic treatment comprises a first treatment section, in which negative pressure therapy is performed by means of the swelling polymer comprising the vacuum device, and a following second treatment section, in which the therapeutic treatment is performed using a wound dressing without generating a negative pressure, wherein the wound dressing comprises an absorbent body, which comprises a swellable polymer, in particular a superabsorbent polymer.
  • the swellable polymer is used in particular for producing a wound dressing of the vacuum device.
  • the invention according to the second aspect therefore provides:
  • a swellable polymer for use in the therapeutic treatment of wounds on the human or animal body wherein the swellable polymer is preferably contained in an absorbent and this preferably in a wound dressing, characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy a device for negative pressure therapy of wounds is performed, and a subsequent second treatment section comprises, in which the therapeutic treatment using the swellable polymer or preferably using the swellable polymer containing the absorbent body or preferably using the swellable polymer containing in The absorbent pad contained in the wound dressing is carried out without generating a negative pressure. Accordingly also provided:
  • An absorbent body for use in the therapeutic treatment of wounds on the human or animal body wherein the absorbent body comprises a swellable polymer, in particular a superabsorbent polymer, and is preferably contained in a wound dressing, characterized in that the therapeutic treatment comprises a first therapy section, in which a wound therapy is performed by means of negative pressure, and a subsequent second treatment section, in which the therapeutic treatment is carried out using the absorbent body without generating a negative pressure.
  • the invention under this second aspect also relates to:
  • a swellable polymer for the production of an absorbent body for use in the therapeutic treatment of wounds on the human or animal body, wherein the absorbent body is preferably contained in a wound dressing, characterized in that the therapeutic treatment comprises a first therapy section in which negative pressure therapy by means of a A device for negative pressure therapy of wounds is performed, and a subsequent second therapy section, in which the therapeutic treatment using the swellable polymer-containing absorbent body is carried out without generating a negative pressure.
  • the subject matter of the invention is also a wound dressing for use in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer in that the wound dressing is used when the inflammatory phase subsides after a previous negative-pressure therapy.
  • the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer in that the wound dressing is used when the inflammatory phase subsides after a previous negative-pressure therapy.
  • the invention also relates to a swellable polymer, preferably contained in a wound dressing, for use in the therapeutic treatment of wounds on the human or animal body, wherein the swellable polymer is preferably contained in a absorbent body in the wound dressing, characterized in that the swellable Polymer or the wound dressing is used on decay of the inflammatory phase after a previous negative pressure therapy or the corresponding use of a swellable polymer in the preparation of this wound dressing.
  • the subject of the invention is also a wound dressing for use in the therapeutic treatment of wounds on the human or animal body, the wound dressing comprising a absorbent body comprising a swellable polymer, in particular a superabsorbent polymer, characterized in that the wound dressing in a second
  • the first phase of therapy comprises a negative pressure therapy by means of a device for negative pressure therapy of wounds and wherein the second therapy phase is carried out using the wound dressing without generating a negative pressure.
  • the terms "therapy section” and “therapy phase” are used synonymously here.
  • the invention also relates to a swellable polymer, preferably in a wound dressing, for use in the therapeutic treatment of wounds on the human or animal body, wherein the swellable polymer is preferably contained in a absorbent body in the wound dressing, characterized in that the swellable polymer or the wound dressing is used in a second therapy phase after a first therapy phase aimed at combating inflammation and / or edema, wherein the first therapy phase comprises a negative pressure therapy by means of a device for negative pressure therapy of wounds and wherein the second therapy phase using the swellable polymer or the Wound dressing is performed without generating a negative pressure. or the corresponding use of a swellable polymer in the manufacture of this wound dressing.
  • the invention furthermore relates to a wound dressing for use in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer, characterized in that the wound dressing is used for increased stimulation of the formation of Granulation tissue is used in the wound area after a previous negative pressure therapy.
  • the invention also relates to the use of such a wound dressing for increased stimulation of the formation of granulation tissue in the wound area after a previous negative pressure therapy in the therapeutic treatment of wounds on the human or animal body.
  • the invention thus also provides a swellable polymer for use in the therapeutic treatment of wounds on the human or animal body, wherein the swellable polymer is preferably contained in a absorbent in a wound dressing, characterized in that the swellable polymer or the wound dressing to reinforced Stimulation of the formation of granulation tissue in the wound area after a previous negative pressure therapy is used or the corresponding use.
  • the invention furthermore relates to a wound dressing for use in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer, characterized in that the wound dressing is used for increased stimulation of the Neovascularization in the wound area after a previous negative pressure therapy is used.
  • the invention also relates to the use of such a wound dressing for increased stimulation of vessel formation in the wound area after a previous negative pressure therapy in the therapeutic treatment of wounds on the human or animal body.
  • the invention thus also provides a swellable polymer for use in the therapeutic treatment of wounds on the human or animal body, wherein the swellable polymer is preferably contained in a absorbent in a wound dressing, characterized in that the swellable polymer or the wound dressing to reinforced Stimulation of neovascularization in the wound area is used after a previous negative pressure therapy; or the corresponding use of the swellable polymer.
  • the invention furthermore relates to a wound dressing for use in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer, characterized in that the wound dressing increases the fibroblast density in the superficial granulation tissue of a wound after a previous negative pressure therapy is used.
  • the wound dressing also relates to the use of such a wound dressing for increasing the fibroblast density in the superficial granulation tissue of a wound after a previous negative pressure therapy in the therapeutic treatment of wounds on the human or animal body.
  • the invention thus also provides a swellable polymer for use in the therapeutic treatment of wounds on the human or animal body, wherein the swellable polymer is preferably contained in a absorbent in a wound dressing, characterized in that the swellable polymer or the wound dressing to increase the fibroblast density is used in the superficial granulation tissue of a wound after a previous negative pressure therapy; or the corresponding use.
  • the literature describes three major healing phases of a wound, especially in wounds with tissue loss.
  • phase 1 inflammatory or exudative phase for haemostasis and wound cleansing
  • phase 2 proliferative phase for the formation of granulation tissue
  • phase 3 epithelization phase
  • the inflammatory phase usually occurs immediately after wound formation. It is characterized by vascular constriction, activation of the coagulation cascade and complex immunological processes. The release of chemically attractive substances (e.g., chemokines) can cause a local inflammatory response. There are four main signs of inflammation: edema, exudation, redness and pain. The surrounding vessels can expand and inflammatory cells migrate into the site of inflammation. These can eliminate microorganisms and tissue necroses. This can be done a cleaning of the wound.
  • chemically attractive substances e.g., chemokines
  • the first treatment section preferably comprises only the inflammatory phase or part of the inflammatory phase.
  • the first therapy section preferably extends to the decay or completion of the inflammatory phase.
  • the decay of the inflammatory phase is recognizable to the physician as the disappearance of one or more of the inflammatory symptoms: edema, exudation, redness and pain.
  • the first treatment section is terminated before a visible granulation is recognizable.
  • the duration of the first part of the therapy depends on the individual circumstances. However, successes have already been achieved when the first treatment section extends over a period of only 1, 2, 3, 4, 5, 6, 7 or 8 days, e.g. between 3 and 7 or 4 and 6 days, especially 4 days. This period of time is shorter than the typical duration of a negative pressure therapy. In particular, the negative pressure therapy no longer needs to be performed until the wound closure.
  • the second therapy section is also to be adapted to individual circumstances, but may, for example, advantageously over a period of 1 to 1000 days, preferably from two to one hundred days, e.g. three to twenty days, especially four to ten days.
  • the second therapy section directly follows the first therapy section.
  • the device to be used according to the invention for carrying out wound therapy by means of negative pressure may be a device known from the prior art.
  • the device for carrying out the negative pressure therapy (a) an air-impermeable cover material for airtight sealing of wound and wound environment, whereby a wound space is formed,
  • a wound dressing which preferably comprises an open-celled foam.
  • the vacuum therapy device which can be used according to the invention comprises a covering material (a) for the airtight sealing of the wound.
  • a covering material for the airtight sealing of the wound.
  • Airtight sealing is not to be understood here as meaning that no gas exchange takes place between the wound space and its surroundings. Rather, by “airtight sealing” in this context is meant that the vacuum necessary for the negative pressure therapy can be maintained. It can therefore also be used covering materials which have a slight gas permeability, as long as necessary for the negative pressure vacuum can be maintained.
  • the airtight cover material may be in the form of, for example, a shell made of a solid material or in the form of a flexible film. Also conceivable are combinations of these.
  • the covering material for airtight sealing of the wound comprises a water-insoluble polymer or a metal foil.
  • the cover material preferably has a thickness of 10 ⁇ m to 10,000 ⁇ m, in particular of 25 ⁇ m to 100 ⁇ m.
  • the covering material (a) is a water-insoluble polymer.
  • the water-insoluble polymer preferably has a solubility of 10 mg / l or less, more preferably of 1 mg / ml or less, in particular of 0.0001 to 1 mg / ml (determined in accordance with the column elution method according to EU guideline RL67-548-EWG, Annex V, Chapter A6).
  • Examples are polyurethane, polyester, polypropylene, polyethylene, polyamide or polyvinyl chloride, polyorganosiloxane (silicone), or a mixture thereof.
  • the polymers mentioned are preferably present in non-cellular form.
  • the cover material has a water vapor permeability of 100 to 2500 g / mx 24, more preferably from 500 to 2000 g / m 2 x 24h, even more preferably from 800 to 1,600 g / m 2 x 24 h, in particular 1050 to 1450 g / m 2 x 24 h, determined according to DIN EN 13726-2 at 23 ° C and 85% relative humidity, on.
  • cover material and finished products can be used which have the aforementioned properties.
  • the polyurethane film of the brand Hydrofilm® (Paul Hartmann AG, Germany) or Visulin® (Paul Hartmann AG, Germany) has proven to be a suitable covering material for the vacuum therapy device to be used according to the invention.
  • the cover material is usually attached in the wound environment or at the wound edge so that an airtight wound closure is ensured. It may be expedient if the cover material is fully self-adhesive or has a self-adhesive edge. Alternatively, attachment and sealing can be done, for example, with an adhesive film, with a liquid adhesive or with a sealing compound. However, it is also possible that the covering material is held only by the negative pressure generated during the vacuum treatment at the wound.
  • the device for negative pressure therapy to be used according to the invention comprises a means (b) for providing fluid communication between the wound space and a negative pressure source located outside the covering material, so that a negative pressure can be produced in the wound space and liquid can be sucked out of the wound space.
  • negative pressure in the wound space in the context of the invention means a reduced air pressure within the wound dressing compared to the ambient air pressure (atmospheric air pressure).
  • within the wound dressing is meant the space formed by the covering material and the wound.
  • Negative pressure is often referred to as “negative pressure”.
  • the fluid communication can be made for example with a connection line and / or with a vacuum fitting. Vacuum fittings are known in the art as "port”.
  • the means for the functional connection of the wound space with a vacuum source located outside the covering material is at least one connecting line.
  • the at least one connecting line can be passed through the covering material.
  • the at least one connecting line can be carried out under the edge of the covering material.
  • the passage point must be hermetically sealed, so that the desired negative pressure in the dressing can be maintained.
  • a sealant for example, an adhesive film, an adhesive, or an adhesive strip is suitable.
  • the connection line can be, for example, a hose, a pipe or another body with a cavity.
  • a suitable tube is, for example, a silicone drainage tube.
  • the means for operatively connecting the wound space to a source of negative pressure external to the cover material is a vacuum connector (port) which can be secured to one of the inner or outer sides of the cover material, the cover material having suitable openings having.
  • a vacuum connector port
  • the seal can be made for example with an adhesive film, with an adhesive, or with an adhesive strip.
  • the port itself has corresponding fastening devices, such as adhesive surfaces, grouted.
  • the cover material (a) and the means for providing fluid communication between the wound space and a vacuum source (b) located outside the cover material are already provided ready for use interconnected.
  • the inventive device for negative pressure therapy nor component (c), the wound dressing, the open-cell foam comprises or consists of this.
  • open-celled means that in the foam (c) at least 60% open cells, preferably at least 90% open cells, more preferably at least 98% open cells, in particular substantially 100% open cells, based on the total number of cells , available.
  • the wound dressing (c) of the vacuum device for example, also allows a substantially even distribution of the negative pressure in the wound space.
  • the open-cell foam to be used according to the invention is a polyurethane foam obtainable by reacting a mixture comprising the components (i) polyisocyanate, (ii) polyol, preferably polyester polyol, (iii) blowing agent, and (iv) catalyst.
  • polyisocyanates As polyisocyanates (i-PUR) it is possible to use generally known aliphatic, cycloaliphatic and / or especially aromatic polyisocyanates become.
  • diphenylmethane diisocyanate (MDI), in particular 4,4'-diphenylmethane diisocyanate (4,4'-MDI), mixtures of monomeric diphenylmethane diisocyanates and higher-nuclear homologues of diphenylmethane diisocyanate (PMDI), tetramethylene diisocyanate (TMDI), are suitable for the preparation of the polyurethanes.
  • PMDI diphenylmethane diisocyanate
  • TMDI tetramethylene diisocyanate
  • HDI Hexamethylene diisocyanate
  • TDI tolylene diisocyanate
  • polyesterols As isocyanate-reactive compounds (ii-PUR), polyols such as polyetherols and / or polyesterols are usually used. Polyester polyols are preferably used in the component (ii-PUR).
  • the polyesterols (II-PUR) used are generally prepared by condensation of polyfunctional alcohols, preferably diols, having 2 to 12 carbon atoms, preferably 2 to 6 carbon atoms, with polyfunctional carboxylic acids having 2 to 12 carbon atoms, preferably 4 to 8 carbon atoms. Examples of suitable acids are succinic acid, glutaric acid, adipic acid, phthalic acid, isophthalic acid, and / or terephthalic acid and mixtures thereof. Adipic acid is particularly preferred.
  • dihydric and polyhydric alcohols examples include ethanediol, diethylene glycol, 1, 4-butanediol, 1, 5-pentanediol, and / or 1, 6-hexanediol and mixtures thereof. 1,4-butanediol is particularly preferred.
  • the compounds (ii-PUR) may be used in admixture with chain extenders and / or crosslinkers.
  • catalysts (iv-PUR) it is possible to use compounds which accelerate the reaction of component (i-PUR) with component (ii-PUR).
  • tertiary amines and / or organic metal compounds in particular tin compounds.
  • the following compounds can be used as catalysts: triethylenediamine, aminoalkyl and / or aminophenylimidazoles and / or tin (II) salts of organic carboxylic acids.
  • Catalysts are generally used in an amount of 0.1 to 5 wt .-% based on the weight of the component (ii-PUR).
  • blowing agent iii-PUR
  • blowing agent iii-PUR
  • a physically acting propellant water may preferably be used, which forms by reaction with the isocyanate groups carbon dioxide.
  • physical blowing agents are (cyclo) aliphatic hydrocarbons, preferably those having 4 to 8, more preferably 4 to 6 and especially 5 carbon atoms, partially halogenated hydrocarbons or ethers, ketones or acetates. The amount of blowing agent used depends on the desired density of Foams. The different blowing agents can be used individually or in any mixtures with each other.
  • blowing agent generally in an amount of 0.1 to 5 wt .-%, in particular from 2.5 to 4 wt .-%, based on the weight of component (ii-PUR).
  • Physical blowing agents are preferably used in an amount of ⁇ 0.5% by weight, based on the weight of component (II-PUR).
  • the reaction is optionally carried out in the presence of (v-PUR) auxiliaries and / or additives, such as.
  • auxiliaries such as.
  • the open-celled polyurethane foam is obtainable by reacting a mixture comprising or consisting of the following components:
  • polyester polyol wherein the polyester polyol is preferably obtainable by reacting a dicarboxylic acid having 4 to 8 carbon atoms with a dialcohol having 2 to 6 carbon atoms and / or preferably one weight average molecular weight of 500 to 4000 g / mol, (iii) blowing agent, and (iv) catalyst.
  • the open-cell foam, in particular polyurethane foam, after three days of storage in bovine serum has a tensile strength between 80 kPa and 300 kPa, measured according to DIN 53571.
  • the open-cell foam in particular polyurethane foam, an air permeability of 1000 to 8000 l / (m 2 sec), measured according to DIN EN ISO 9237.
  • the wound dressing (c) of the vacuum device silver in the form of silver ions or in the form of atomic silver contain.
  • silver is applied in the form of a silver coating on the wound dressing.
  • the silver may be distributed within the wound dressing.
  • the foam (c) contains 0.000001 to 0.1% by weight, more preferably 0.0001 to 0.01% by weight of silver, based on the total weight of the foam (c).
  • the wound dressing (c), in particular the open-cell foam has a thickness of 1 to 50 mm, in particular 15 mm to 30 mm.
  • the device for negative pressure therapy of wounds comprises at least one wound contact layer for introduction between wound dressing (c) and wound surface.
  • the additional wound contact layer may be adhesively or non-adhesively bonded to the wound dressing (c).
  • any wound contact layer known from the prior art may be considered wound contact layer as long as, on the one hand, passage of wound exudate is ensured and, on the other hand, the material has no tendency to coalesce or adhere to the wound tissue.
  • Especially suitable wound contact layers are ointment of Hydrotul ® brand Atrauman ® and Atrauman Ag ® (Paul Hartmann AG, Germany).
  • devices for negative pressure therapy of wounds can be used which (as wound dressing (c)) contains an open-celled foam based on a crosslinked polyorganosiloxane.
  • wound dressing (c) contains an open-celled foam based on a crosslinked polyorganosiloxane.
  • An advantage of the open-celled foam based on a crosslinked polyorganosiloxane is that it provides a soft wound dressing for the negative pressure therapy of wounds and ensures a uniform pressure distribution on the wound base. By providing a soft wound dressing and even pressure distribution, the vacuum treatment can be carried out gently and effectively.
  • the device for negative pressure therapy of wounds comprises at least one additional pressure distribution layer between the wound dressing (c) and the covering material (a).
  • the advantage of an additional pressure distribution layer may be that the pressure exerted by the dressing on the wound base is more evenly distributed by the use of the pressure distribution layer.
  • the pressure distribution layer can store and / or forward additional wound exudate.
  • the additional pressure distribution layer may be an open cell or semi-open cell foam, a spacer fabric, a textile layer, a structured gel, or a permeable nonwoven layer.
  • Suitable textile layers include ES compresses or lattice garb.
  • the additional pressure distribution layer may be configured such that fluid, such as wound exudate, is passed therethrough. This can be the Pressure distribution layer containing suitable channels or openings, or consist of a liquid-permeable material.
  • first wound dressing is basically not to be confused with the wound dressing for wound therapy according to the invention, which is used in the second therapy section and is described in more detail below (“second wound dressing”). It is noted, however, that the wound dressings described below are in principle also suitable as wound dressings (c) and are correspondingly included in the present invention.
  • the second treatment section is generally performed "without negative pressure". It is not to be understood that a wound treatment with vacuum device, however, is carried out without applied negative pressure. Rather, it is to be understood that the use of a vacuum device is completely dispensed with in the second therapy section.
  • the wound dressing (“second wound dressing”) is generally a wound dressing which allows wound treatment in a moist or moist environment, moist or moist wet means that the wound under the wound dressing has a moist or moist surface, ie the wound does not dry (at least not completely) below the surface
  • the wound dressing (“second wound dressing”) comprises an absorbent body which comprises a swellable polymer, in particular a superabsorbent polymer.
  • the wound dressing comprises an absorbent which comprises an at least partially liquid-permeable cover and, arranged therein, a swellable polymer, in particular a superabsorbent polymer.
  • a swellable polymer in particular a superabsorbent polymer.
  • the swellable polymer is surrounded by the shell.
  • the at least partially liquid-permeable casing allows the passage of liquids over its entire surface or at least in certain areas of the shell.
  • the shell may consist of a single material or include several materials.
  • the sheath may advantageously be or comprise a textile (surface) material, such as a knitted fabric, a knitted fabric or a woven fabric, in particular of polyolefin, in particular of polypropylene.
  • the sheath can advantageously at least partially consist of a textile surface which is non-elastically extensible in the longitudinal, transverse and diagonal directions, as disclosed in EP 0 594 034.
  • the swellable polymer to be used in the invention is or preferably comprises a superabsorbent polymer.
  • a superabsorbent polymer (SAP) is generally understood to mean a water-insoluble, swellable polymer which can take up many times its own weight of liquid, for example water. The fluid intake leads to the formation of a hydrogel.
  • the term superabsorbent polymer is understood in particular to mean a polymer which according to the standard test method WSP 240.2 (05) has a free swell capacity of at least 10 g / g, preferably at least 20 g / g having.
  • WSP 240.2 (05) for determining the w value is described in "Standard Test Methods for the Nonwoven and Related Industries", Edition 2008 (edited by "EDANA, International Association Serving the Nonwoven and Related Industries", Cary, NC, USA and “INDA, Association of the Nonwovens Fabrics Industry", Brussels, Belgium).
  • WSP 240.2 (05) according to EDANA is a standard test method for determining the w value ("free swell capacity") of superabsorbent polyacrylate powder. According to WSP 240.2 (05), the free uptake capacity for a 0.9 weight percent saline solution is determined.
  • the determination of the w value of superabsorbent material which is not polyacrylate powder is carried out in a corresponding manner.
  • the sup ⁇ erabsorb Schlierende polymer may be in the form of fibers or particles preferably.
  • the term "swellable polymer” preferably refers to polymers which are in principle capable of swelling, regardless of whether the polymer is in an unswollen or swollen state, that is, if a swellable polymer has come into contact with water is present as an already swollen polymer, it is still considered as a "swellable polymer" within the meaning of the invention.
  • the superabsorbent polymer is or comprises polyacrylate.
  • the monomer content is in particular more than 70, for example more than 80 or 95 percent by weight of acrylic acid and / or a salt thereof (based on the total weight of the polyacrylate).
  • the polyacrylate may be present as a homopolymer, copolymer or block polymer.
  • the polyacrylate is preferably present as a partially neutralized polymer, in particular the degree of neutralization should be between 20% and 90%, more preferably between 45% and 80%.
  • the absorbent body comprises a mixture of polyacrylate particles, wherein the particle mixture contains polyacrylate particles of different sizes, characterized in that the particle mixture a) contains 5 to 100% by weight, preferably 5 to 98 wt .-%, particles having a particle size x with x ⁇ 300 ⁇ , and b) 0 to 95 wt .-%, preferably 2 to 95 wt .-%, particles having a particle size x with x> 300 ⁇ , contains.
  • the particle size is determined in the context of the present invention analogously to ED ANA 420.2-02, wherein the sieves (diameter 200 mm) have the appropriate hole sizes.
  • sieves with other hole sizes such as 125 ⁇ , 160 ⁇ , 630 ⁇ , 900 ⁇ , and 1500 ⁇ ⁇ can be used.
  • dry polyacrylate particles having a moisture content of less than 10% by weight of water, based on the total weight of the particles, are used, the moisture content being determined according to EDANA 450.2-02.
  • the absorbent body may further comprise a nonwoven fabric.
  • the nonwoven can serve as a carrier material for the swellable polymer.
  • the swellable polymer according to the invention may preferably be applied or incorporated on a nonwoven as carrier material.
  • These Arrangement is preferably part of the absorbent body or forms the absorbent body.
  • the absorbent is preferably part of the wound dressing.
  • the nonwoven is preferably a hydrophilic fiber material.
  • the fibers of the hydrophilic fiber material may be, for example, water-insoluble fibers of cellulose, e.g. largely delignified engineering pulp fibers, e.g. Wood pulp fibers, preferably with a fiber length of ⁇ 5 mm or include.
  • the nonwoven may also contain or consist of hydrophilic fiber material of regenerated cellulose, carboxymethylcellulose, carboxyethylcellulose, hydroxymethylcellulose or hydroxyethylcellulose.
  • It may also be based on or consist of a mixture of fibers of cellulose, regenerated cellulose, carboxymethylcellulose, carboxyethylcellulose, hydroxymethylcellulose or hydroxyethylcellulose and thermoplastic fibers, for example of polyethylene, polypropylene or polyester.
  • the swellable or superabsorbent polymer is preferably distributed in the form of particles in the web.
  • the absorbent body comprises at least one superabsorbent polyacrylate and a nonwoven which comprises a mixture of cellulose fibers and polypropylene fibers or is based on such a mixture.
  • the fleece can serve as a carrier material.
  • the fibers can be processed into a layer together with particles or fibers of the superabsorbent polymer in a so-called airlaid process.
  • the absorbent body is a wrapped airlaid comprising a superabsorbent polyacrylate, cellulosic and polypropylene fibers.
  • the absorbent body is subjected to a solution.
  • the application is preferably carried out to saturation and preferably with an aqueous solution which swells the swellable or superabsorbent material and turns it into a gelatinous state.
  • the aqueous solution is preferably saline.
  • the absorbent body can be acted upon, for example, with at least 600 weight percent, at least 800 weight percent, or at least 1000 weight percent of an aqueous solution, based on the weight of the dry absorbent body.
  • the absorbent body is preferably applied with less than 5000 percent by weight, for example less than 3500 percent by weight, for example less than 2500 percent by weight, of an aqueous solution.
  • the absorbent body contains that amount of an aqueous activation solution which corresponds to its maximum absorption capacity for Ringer's solution.
  • the maximum uptake capacity for Ringer's solution can be determined according to the aforementioned test method WSP 240.2 (05), but a) instead of the saline solution used in WSP 240.2 (05) Ringer solution is used and b) instead of the sealed in a shell test substance ("Bag" according to Section 6.1 of WSP 240.2 (05)) of the absorbent body according to the invention is used.
  • the maximum absorption capacity corresponds to the gravimetrically determined weight difference between the dry absorbent body and the activated absorbent body, whereby a deviation of the weight difference by 15% is included upwards or downwards.
  • the aqueous solution is a synthetic solution and does not contain body fluids or body-separated fluids.
  • the aqueous solution contains more than 50, eg more than 70, more than 80, more than 90 or 100 volume percent water. It can contain at least 5 mmol / l of sodium ions, at least 0.1 mmol / l of potassium ions, at least 0.1 mmol / l of calcium ions and / or at least 5 mmol / l of chloride ions.
  • the aqueous solution contains further inorganic cations and / or anions, optionally organic anions, and optionally additions of bioorganic compounds.
  • the pH is preferably 4 to 9. The viscosity at 20 ° C.
  • the aqueous solution is a Ringer's solution.
  • a Ringer's solution is meant an approximately to the blood iso-osmotic synthetic solution comprising sodium chloride, potassium chloride and calcium chloride dissolved in distilled water.
  • the Ringer solution preferably contains 147 mmol / l sodium ions, 4.0 mmol / l potassium ions, 3.0 mmol / l calcium ions and 157 mmol / l chloride ions, whereby a deviation of the respective ion concentration from the stated value by 5% is possible ,
  • an advantage of the applied absorbent solution is that immediately after the start of therapy, the wound is kept in a moist environment and does not dry out, which promotes the healing of wounds.
  • the absorbent body for example as an alternative or in addition to the aqueous solution described above, an antimicrobial Include substance.
  • the antimicrobial substance is or comprises a substance with antimicrobial activity, which is present in cationic form at pH values of from 4 to 7.5, for example substances having amino or imino groups.
  • the cationic antimicrobial substance can be antimicrobially active metal cations, in particular silver cations, for example a complex of l-vinyl-2-pyrrolidone with silver cations.
  • Particularly suitable cationic substances with antimicrobial action are biguanide derivatives such as chlorhexidine or polybiguanides, such as polyethylene biguanide (PEB), polytetramethylene biguanide (PTMB) or polyethylene hexamethylene biguanides (PEHMB).
  • biguanide derivatives such as chlorhexidine or polybiguanides, such as polyethylene biguanide (PEB), polytetramethylene biguanide (PTMB) or polyethylene hexamethylene biguanides (PEHMB).
  • PEB polyethylene biguanide
  • PTMB polytetramethylene biguanide
  • PEHMB polyethylene hexamethylene biguanides
  • a particularly preferred polybiguanide is polyhexamethylene biguanide (PHMB or polyhexanide).
  • polyguanidines such as polyhexamethyleneguanidines (PHMG), N-octyl-l - [10- (4-octyliminopyridin-1-yl) decyl] pyridin-4-imine (octenedin), quaternary ammonium compounds such as, for example, benzalkonium chloride or cetylpyridinium chloride, triazines such as, for example, 1- (3-chloroallyl) -3,5,7-triaza-1-azoniaadamantane chloride or the ammonium compound taurolidine.
  • PHMG polyhexamethyleneguanidines
  • quaternary ammonium compounds such as, for example, benzalkonium chloride or cetylpyridinium chloride
  • the wound dressing according to the invention can also contain a wound contact layer and an evaporation-inhibiting backing layer.
  • the wound dressing comprises
  • the wound contact layer (i) is preferably a partially and / or structured applied, atraumatic coating.
  • the coating can be applied directly to the absorbent body. Preferably, it is applied to a suction body, which is surrounded by the textile cover described above.
  • the coating is preferably a silicone coating, wherein the coating may be, for example, porous and formed by a plurality of relatively thin strips or lines or island-shaped areas which may be separated from each other by uncoated areas. In these uncoated areas, the wound-facing side of the absorbent body may be exposed to the wound.
  • the atraumatically acting coating can thus form a supernatant, whereby on the one hand a gluing of the absorbent body with wound tissue can be prevented and on the other hand a certain small distance between the wound-facing side of the absorbent body and the Wound tissue can be retained.
  • the porous shell layer material can remain open three-dimensionally and provide or maintain less resistance to fluid passage in both directions over the useful life of the wound dressing.
  • the wound-facing side of the absorbent body can be covered by a film, preferably a plastic film.
  • the film is preferably substantially germ and waterproof and thus provides improved protection against evaporation.
  • Wound dressing can be applied to a wound or used to stamp out deep wounds.
  • the present invention is particularly advantageous when the wounds are burn wounds, wounds resulting from mechanical trauma, a wound resulting from the action of chemicals, a wound caused by a metabolic disorder, a wound caused by a circulatory disturbance, or a wound caused by a pressure ulcer wound acts.
  • treatment 1 included 8 days of negative pressure therapy
  • treatment 2 included a first treatment session with 4 days of negative pressure therapy, followed immediately by a second treatment session with 4 days of therapy in wet or damp Milieu.
  • treatment 3 included a first therapy session with 6 days of negative pressure therapy, followed immediately by a second therapy session with 2 days of therapy in a damp or moist wet environment.
  • the TenderWet ® Plus product (Paul Hartmann AG) was used as wound dressing for the second therapy section, for the negative pressure therapy were polyurethane film (Hydrofilm, Paul Hartmann AG) as covering material (a) and open-cell foam as wound dressing (c) (Vivanomed ® , Paul Hartmann AG) together with commercial adapter, hose (fluid communication means b) and vacuum device used.
  • FIG. 1 shows that in the treatments B2 according to the invention (4 days underpressure + 4 days moist medium) and B3 (6 days underpressure + 2 days moist medium) the formation of granulation tissue is considerable compared to a negative pressure Bl of the same duration (8 days) has improved.
  • FIG. 2 shows that in the treatments B2 according to the invention (4 days underpressure + 4 days moist medium) and B3 (6 days underpressure + 2 days moist medium), the neo-vascularization improves compared to a negative-pressure therapy B1 of the same duration (8 days) Has. A significant improvement in the stimulation of neovascularization could be achieved.
  • FIG. 3 shows that in the treatments B2 according to the invention (4 days underpressure + 4 days moist medium) and B3 (6 days underpressure + 2 days moist medium) the formation of fibroblasts improves compared to a negative pressure Bl of the same duration (8 days) Has. A significant increase in fibroblast density could be achieved.
  • wound exudate was obtained from chronic wounds (Eming et al., 2008). The amount corresponding to 50 micrograms of total protein was mixed with 100 mg FAVOR ® PAC 300 superabsorbent incubated (pre-swollen to saturation with Ringer's solution) for 2 hours.
  • the present invention relates inter alia to the following aspects or embodiments:
  • a product for use in the therapeutic treatment of wounds on the human or animal body comprising a device for the negative pressure therapy of wounds, characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of the device, and a subsequent second therapy section, in which the therapeutic treatment is carried out using a wound dressing without generating a negative pressure, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer.
  • a product for use in the therapeutic treatment of wounds on the human or animal body comprising a wound dressing, and wherein the wound dressing comprises an absorbent body, the swellable polymer, in particular a superabsorbent polymer, characterized in that the therapeutic treatment comprises a first treatment section, in which negative pressure therapy is performed by means of a device for negative pressure therapy of wounds, and a subsequent second therapy section, in which the therapeutic treatment using the wound dressing is performed without generating a negative pressure.
  • a product for use in the therapeutic treatment of wounds on the human or animal body comprising a device for negative pressure therapy of wounds and a wound dressing
  • the wound dressing comprises an absorbent body comprising a swellable polymer, in particular a superabsorbent polymer , characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of the device, and a subsequent second therapy section, in which the therapeutic treatment is performed using the wound dressing without generating a negative pressure.
  • the first treatment section ends, for example, with decay or completion of the inflammatory phase.
  • the first part of the therapy for example, covers a period of 1 to 8 days.
  • the second therapy section begins, for example, during or immediately after the inflammatory phase.
  • the second therapy section extends, for example, over a period of 1 to 8 days.
  • the absorbent body comprises, for example, a liquid-permeable, textile shell and arranged therein a superabsorbent polymer.
  • the wound dressing comprises, for example: i) atraumatic wound contact layer, ii) absorbent body, and iii) preferably evaporation-inhibiting film layer on the side facing away from the wound.
  • the absorbent body includes, for example, a non-woven, which contains, for example, cellulose fibers.
  • the absorbent body can be applied with a solution, preferably Ringer's solution.
  • the absorbent body may comprise an antimicrobial substance.
  • the apparatus for performing negative pressure wound therapy includes, for example, (a) an air-impermeable cover material for hermetically sealing the wound and wound environment, forming a wound space, (b) means for providing fluid communication between the wound space and an outside of the cover material Vacuum source, so that a negative pressure in the wound space can be produced, and liquids are sucked from the wound space, (c) a wound dressing, which allows a substantially uniform distribution of negative pressure in the wound space, preferably a wound dressing containing open-cell foam, in particular open-cell polyurethane foam ,
  • a wound dressing in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent body which comprises a swellable polymer, in particular a superabsorbent polymer, characterized in that the therapeutic treatment comprises a first therapy section in which Underpressure therapy is performed by means of a device for negative pressure therapy of wounds, and that the therapeutic treatment comprises a subsequent second treatment section, which is performed using the wound dressing without generating a negative pressure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne de manière générale le traitement des plaies et en particulier des dispositifs ou systèmes de traitement de plaies. Une première partie du traitement consiste en une thérapie par pression négative, tandis que, dans une deuxième partie, le traitement se fait sans générer de pression négative. Le système comprend un pansement qui contient un polymère gonflant, en particulier un polymère superabsorbant.
EP13722291.5A 2012-09-25 2013-05-14 Système de traitement de plaies Withdrawn EP2900293A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13722291.5A EP2900293A1 (fr) 2012-09-25 2013-05-14 Système de traitement de plaies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12006687.3A EP2711033A1 (fr) 2012-09-25 2012-09-25 Système de traitement des plaies
EP13722291.5A EP2900293A1 (fr) 2012-09-25 2013-05-14 Système de traitement de plaies
PCT/EP2013/001417 WO2014048514A1 (fr) 2012-09-25 2013-05-14 Système de traitement de plaies

Publications (1)

Publication Number Publication Date
EP2900293A1 true EP2900293A1 (fr) 2015-08-05

Family

ID=46980694

Family Applications (2)

Application Number Title Priority Date Filing Date
EP12006687.3A Withdrawn EP2711033A1 (fr) 2012-09-25 2012-09-25 Système de traitement des plaies
EP13722291.5A Withdrawn EP2900293A1 (fr) 2012-09-25 2013-05-14 Système de traitement de plaies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP12006687.3A Withdrawn EP2711033A1 (fr) 2012-09-25 2012-09-25 Système de traitement des plaies

Country Status (6)

Country Link
US (1) US9445948B2 (fr)
EP (2) EP2711033A1 (fr)
CN (1) CN104582749A (fr)
HK (1) HK1205021A1 (fr)
RU (1) RU2628061C2 (fr)
WO (1) WO2014048514A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012025125A1 (de) 2012-12-21 2014-06-26 Paul Hartmann Ag Saugkörper zur therapeutischen Behandlung einer Wunde mittels Unterdruck
DE102012025124A1 (de) 2012-12-21 2014-06-26 Paul Hartmann Ag Saugkörper zur therapeutischen Behandlung einer Wunde mittels Unterdruck
DE102014106518A1 (de) * 2014-05-09 2015-11-12 Paul Hartmann Ag Schaumwundauflage für die Unterdrucktherapie
US10973693B2 (en) 2015-05-18 2021-04-13 Smith & Nephew Plc Negative pressure wound therapy apparatus and methods
EP3334472B1 (fr) * 2015-08-13 2023-11-22 Smith&Nephew, Inc. Systèmes et procédés pour la mise en oeuvre d'une thérapie par pression réduite
WO2018150267A2 (fr) 2017-02-15 2018-08-23 Smith & Nephew Pte. Limited Appareils de traitement de plaie par pression négative et leurs procédés d'utilisation
WO2019063467A1 (fr) 2017-09-29 2019-04-04 T.J.Smith And Nephew,Limited Appareil de traitement des plaies par pression négative à panneaux amovibles
GB201813282D0 (en) 2018-08-15 2018-09-26 Smith & Nephew System for medical device activation and opertion
GB201804347D0 (en) 2018-03-19 2018-05-02 Smith & Nephew Inc Securing control of settings of negative pressure wound therapy apparatuses and methods for using the same
WO2019199798A1 (fr) * 2018-04-13 2019-10-17 Kci Licensing, Inc. Contrainte de compression et indicateur de distribution de pression négative pour pansement
WO2019211731A1 (fr) 2018-04-30 2019-11-07 Smith & Nephew Pte. Limited Systèmes et procédés de commande d'appareil de thérapie de plaie à pression négative à double mode
GB201806988D0 (en) 2018-04-30 2018-06-13 Quintanar Felix Clarence Power source charging for negative pressure wound therapy apparatus
USD888225S1 (en) 2018-04-30 2020-06-23 Smith & Nephew Asia Pacific Pte. Limited Pump and canister assembly for negative pressure wound therapy
GB201808438D0 (en) 2018-05-23 2018-07-11 Smith & Nephew Systems and methods for determining blockages in a negative pressure wound therapy system
RU2711570C1 (ru) * 2018-10-30 2020-01-17 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПбГПМУ Минздрава России) Способ остановки наружного кровотечения

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645081A (en) 1991-11-14 1997-07-08 Wake Forest University Method of treating tissue damage and apparatus for same
EP0594034B1 (fr) 1992-10-22 1997-01-08 IVF Hartmann AG Compresse à déformation plastique
US5465735A (en) * 1994-12-01 1995-11-14 The Kendall Company Wound dressing
US6169223B1 (en) * 1999-02-08 2001-01-02 Internationale Verbandstoff Fabrik Schaffhausen Compress for medical treatment
US7361184B2 (en) * 2003-09-08 2008-04-22 Joshi Ashok V Device and method for wound therapy
US7531711B2 (en) * 2003-09-17 2009-05-12 Ossur Hf Wound dressing and method for manufacturing the same
GB0508528D0 (en) * 2005-04-27 2005-06-01 Smith & Nephew SAI with macrostress
US20110313373A1 (en) * 2004-11-02 2011-12-22 Birgit Riesinger Device for the treatment of wounds using a vacuum
DE202004017052U1 (de) * 2004-11-02 2005-06-09 Riesinger, Birgit Vorrichtung zur Wundbehandlung unter Einsatz von Unterdruck
US20070027414A1 (en) * 2005-07-28 2007-02-01 Integra Lifesciences Corporation Laminar construction negative pressure wound dressing including bioabsorbable material
CN101299978A (zh) * 2005-11-02 2008-11-05 比尔吉特·雷森格 附着于人类或动物皮肤表面的吸收用品
MX348927B (es) * 2006-02-07 2017-07-04 Smith & Nephew Inc Vendaje quirúrgico para heridas.
GB0606661D0 (en) * 2006-04-03 2006-05-10 Brightwake Ltd Improvements relating to dressings
DE102006047041A1 (de) * 2006-10-02 2008-04-10 Birgit Riesinger Flächenhafter Absorptionskörper
RU62504U1 (ru) * 2006-12-07 2007-04-27 Юрий Павлович Савченко Устройство для дренирования средостения
US8377016B2 (en) * 2007-01-10 2013-02-19 Wake Forest University Health Sciences Apparatus and method for wound treatment employing periodic sub-atmospheric pressure
DE102008034363A1 (de) * 2007-08-03 2009-02-05 Birgit Riesinger Wundpflegeartikel mit absorbierender Hülle
WO2009021523A1 (fr) * 2007-08-14 2009-02-19 Coloplast A/S Elément distributeur par pression d'une mousse à cellules fermées
US20110054375A1 (en) 2007-11-27 2011-03-03 Hans Smola Dressing comprising polyacrylate particles and use thereof
GB0723874D0 (en) * 2007-12-06 2008-01-16 Smith & Nephew Dressing
WO2009086580A1 (fr) * 2008-01-07 2009-07-16 Cerulean Medical Pty Ltd Dispositif de traitement à pression négative
US8449508B2 (en) * 2008-03-05 2013-05-28 Kci Licensing, Inc. Dressing and method for applying reduced pressure to and collecting and storing fluid from a tissue site
MX2011003557A (es) * 2008-10-02 2011-09-01 Lrr & D Ltd Vendas para heridas con capa de interfaz.
EP2395958B1 (fr) * 2009-02-12 2017-12-13 Perfuzia Medical, Inc. Dispositifs pour la manipulation de la circulation dans le système circulatoire d'un patient
SE533841C2 (sv) * 2009-06-15 2011-02-01 Moelnlycke Health Care Ab Sårförband med hög vätskehanteringskapacitet
DE102009031992A1 (de) * 2009-07-06 2011-01-13 Paul Hartmann Ag Vorrichtung zur Unterdrucktherapie von Wunden
US9358158B2 (en) * 2010-03-16 2016-06-07 Kci Licensing, Inc. Patterned neo-epithelialization dressings, systems, and methods
DE102010036371A1 (de) * 2010-07-13 2012-01-19 Birgit Riesinger Wundpflegeartikel zur Wundbehandlung unter Einsatz von Unterdruck enthaltend Mikrofasern
US20120046589A1 (en) 2010-08-19 2012-02-23 Axel Eckstein Wound dressing comprising foam and ointment base for negative pressure therapy
DE102010034819A1 (de) * 2010-08-19 2012-02-23 Paul Hartmann Ag Verwendung eines Polyurethanschaumstoffs als Wundauflage in der Unterdrucktherapie
TWI465263B (zh) * 2010-12-10 2014-12-21 Ind Tech Res Inst 醫用敷料及使用該敷料之負壓治療裝置
CN102058932B (zh) * 2010-12-20 2013-03-06 惠州市华阳医疗电子有限公司 负压治疗系统的负压控制装置

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2014048514A1 *

Also Published As

Publication number Publication date
HK1205021A1 (en) 2015-12-11
WO2014048514A1 (fr) 2014-04-03
CN104582749A (zh) 2015-04-29
RU2015110123A (ru) 2016-11-20
EP2711033A1 (fr) 2014-03-26
US20140088527A1 (en) 2014-03-27
RU2628061C2 (ru) 2017-08-14
US9445948B2 (en) 2016-09-20

Similar Documents

Publication Publication Date Title
EP2900293A1 (fr) Système de traitement de plaies
EP3139877B2 (fr) Pansement en mousse pour traitement sous vide
EP2762177B1 (fr) Dispositif de traitement par dépressurisation de plaies
WO2009019227A2 (fr) Article pour le soin des plaies, présentant des polymères super-absorbants sous forme de fibres et/ou de fils
EP2635244B1 (fr) Pansement pour plaie comprenant une couche de biocellulose et équipé pour adsorber des bactéries
WO2009019229A2 (fr) Article pour le soin des plaies, présentant au moins une couche de polymères super-absorbants et une couche de mousse souple
WO2010026251A1 (fr) Article pour le soin des plaies contenant une proportion de fibres naturelles modifiées ou de fibres synthétiques
DE102008037888A1 (de) Wundpflegeartikel, aufweisend Textilbänder mit Fasern mit gelbildenden Eigenschaften sowie Fasern mit nicht gelbildenden Eigenschaften
WO2009019224A2 (fr) Article pour le soin des plaies avec enveloppe absorbante
DE102007049430A1 (de) Wundpflegeartikel, aufweisend mindestens einen Anteil an stützenden Fasern und einen Anteil an hydroaktiven Polymeren
WO2018115257A1 (fr) Hydrogels aqueux pour le traitement de plaies
WO2014096197A1 (fr) Corps d'aspiration pour le traitement thérapeutique d'une plaie par dépression
DE102007063294A1 (de) Wundauflage enthaltend superabsorbierende Polymere
WO2014096229A1 (fr) Corps d'aspiration pour le traitement thérapeutique d'une plaie par dépression
EP1799275B1 (fr) Procede de production d'un pansement
WO2014048513A1 (fr) Polymère gonflant destiné à être utilisé dans le traitement thérapeutique
DE102007049428A1 (de) Wundpflegeartikel, aufweisend mindestens eine Lage aufweisend superabsorbierende Polymere, sowie eine Lage aufweisend einen Weichschaumstoff
EP4134107A1 (fr) Pansement doté d'une couche d'hydrogel et d'une couche de contact avec la plaie comprenant de l'acide hyaluronique
EP3842075B1 (fr) Pansement contenant du siloxane
DD231987B5 (de) Verfahren zur herstellung eines nicht resorbierbaren flachmaterials
WO2009019226A2 (fr) Article pour le soin des plaies comportant un doublage immédiatement adjacent
EP2623136A2 (fr) Couche membranaire à perméabilité variable à base de carragénane ou de chitosan en tant que pansements

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150303

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20170213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20181201